EIF5A2 is a novel chemoresistance gene in breast cancer

Breast Cancer

22, 602-607

DOI: 10.1007/s12282-014-0526-2

Citation Report

#	Article	IF	Citations
1	Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression. Oncotarget, 2014, 5, 6716-6733.	0.8	22
2	Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with earlyâ€stage cervical cancer. Histopathology, 2016, 69, 276-287.	1.6	21
3	Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy. BMC Cancer, 2016, 16, 669.	1.1	17
4	Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer. Trends in Cell Biology, 2016, 26, 918-933.	3.6	96
5	Chromosomal Alterations and Gene Expression Changes Associated with the Progression of Leukoplakia to Advanced Gingivobuccal Cancer. Translational Oncology, 2017, 10, 396-409.	1.7	60
6	N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of acute lymphoblastic leukemia cells to vincristine through inhibition of eif5a-2 activation. Anti-Cancer Drugs, 2017, 28, 1097-1105.	0.7	5
7	GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells. Oncology Reports, 2017, 39, 1283-1291.	1.2	19
8	Eukaryotic translation initiation factor 5A-2 involves in doxorubicin-induced epithelial-mesenchymal transition in oral squamous cell carcinoma cells. Journal of Cancer, 2018, 9, 3479-3488.	1.2	11
9	DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anti-Cancer Drugs, 2018, 29, 774-785.	0.7	12
10	Eukaryotic initiation factor 5A2 and human digestive system neoplasms. World Journal of Gastrointestinal Oncology, 2019, 11, 449-458.	0.8	7
11	MicroRNAâ€383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2. Journal of Cellular and Molecular Medicine, 2019, 23, 7190-7199.	1.6	24
12	High expression of MKK3 is associated with worse clinical outcomes in African American breast cancer patients. Journal of Translational Medicine, 2020, 18, 334.	1.8	19
13	Overexpression of EIF5A2 Predicts Poor Prognosis in Patients with Oral Squamous Cell Carcinoma. Diagnostics, 2020, 10, 436.	1.3	10
14	Long non-coding RNA GAS6-AS1 acts as a ceRNA for microRNA-585, thereby increasingEIF5A2expression and facilitating hepatocellular carcinoma oncogenicity. Cell Cycle, 2020, 19, 742-757.	1.3	18
15	Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer. Oncology Research, 2020, 28, 33-40.	0.6	12
16	Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 26079-26089.	0.8	40
17	Interactions Between lncRNA TUG1 and miR-9-5p Modulate the Resistance of Breast Cancer Cells to Doxorubicin by Regulating eIF5A2. OncoTargets and Therapy, 2020, Volume 13, 13159-13170.	1.0	23
18	MicroRNAâ€'33aâ€'5p overexpression sensitizes tripleâ€'negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelialâ€'mesenchymal transition. Oncology Letters, 2019, 18, 5986-5994.	0.8	18

#	Article	IF	Citations
19	Eukaryotic translation initiation factor 5A in the pathogenesis of cancers (Review). Oncology Letters, 2020, 20, 1-1.	0.8	17
21	GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cells. American Journal of Translational Research (discontinued), 2017, 9, 2608-2617.	0.0	11
22	Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy. International Journal of Oncology, 2020, 57, 1368-1380.	3.9	2
23	Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy. International Journal of Oncology, 2020, 57, 1368-1380.	1.4	2
24	Evidence of antagonistic predictive effects of miRNAs in breast cancer cohorts through data-driven networks. Scientific Reports, 2022, 12, 5166.	1.6	0
25	Androgen receptor regulates eIF5A2 expression and promotes prostate cancer metastasis via EMT. Cell Death Discovery, 2021, 7, 373.	2.0	14
26	EIF5A2 Is Involved in the Biological Process of Cervical Cancer Cells through AGR2. Pharmacology, 0, , 1-10.	0.9	0
27	Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance. Cell Death and Disease, 2022, 13, .	2.7	8
28	High eukaryotic initiation factor <scp>5A2</scp> expression predicts poor prognosis and may participate in the <scp>SNHG16</scp> / <scp>miR</scp> â€10bâ€5p/ <scp>EIF5A2</scp> regulatory axis in head and neck squamous cell carcinoma. Journal of Clinical Laboratory Analysis, 0, , .	0.9	1
29	Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. Cell Death Discovery, 2023, 9, .	2.0	6